Cadence Pharmaceuticals Reports Third Quarter 2009 Financi...(------- Total current assets ...),Health

Date:11/5/2009

------- Total current assets 98,817,405 50,042,616 Property and equipment, net 6,826,161 4,477,020 Restricted cash 189,738 537,586 Other assets 25,082 90,792 ------ ------ Total assets $105,858,386 $55,148,014 ============ =========== Liabilities and Stockholders' Equity Current liabilities: Accounts payable 2,997,956 $4,877,854 Accrued liabilities 5,599,841 9,063,310 Current portion of long-term debt 6,229,049 7,694,173 Other current liabilities 22,048 22,048 ------ ------ Total current liabilities 14,848,894 21,657,385 Deferred rent 725,625 952,274 Long-term debt, less current portion and discount 1,650,996 6,098,113 Total stockholders' equity 88,632,871 26,440,242 ---------- ---------- Total liabilities and stockholders' equity $105,858,386 $55,148,014 ============ ===========

SOURCE Cadence Pharmaceuticals, Inc.

'/>"/>

SOURCE Cadence Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery